Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Transitional Cell

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Urothelial Cancer

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Prostatic Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Metastatic Castration-resistant Prostate Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Prostatic Neoplasms, Recurrence

Prostatic Neoplasms

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms

Urinary Bladder Neoplasms, Ureteral Neoplasms

Metastatic Hormone-sensitive Prostate Cancer

Metastatic Hormone-sensitive Prostate Cancer

Non-Muscle Invasive Bladder Neoplasms

Prostate Cancer Metastatic

Carcinoma, Transitional Cell

Prostatic Neoplasms

Locally Advanced or Metastatic Unresectable Urothelial Cancer

Metastatic Castration Resistant Prostate Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Genital Diseases, Male, Prostatic Diseases

Neoplasms, Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Metastatic Castrate Resistant Prostate Cancer

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistent Prostate Cancer

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Prostatic Neoplasms

Clinical Trials

OPTION-DDR

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

TRIPLE-SWITCH

KLK2-PASenger

THOR

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

MK-2400-001

TroFuse-031

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

BRIDGE

CABA-DOC

ABLE-22

MEVPRO-1

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

rechARge

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

REINFORCE

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

CHAARTED

ARASENS

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

STAMPEDE2

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

TROPiCS-04

TRITON3

KEYNOTE-921

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

CheckMate 7DX

ProBio

PRESIDE

ARASAFE

CAPItello280

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

PEACE1

KEYNOTE-921

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

RANGE

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

DART

Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer

Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

MK-3475-045

Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14